NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free TRDA Stock Alerts $12.45 -0.27 (-2.12%) (As of 02:08 PM ET) Add Compare Share Share Today's Range$12.20▼$12.8950-Day Range$11.58▼$15.1752-Week Range$10.62▼$18.44Volume29,280 shsAverage Volume77,646 shsMarket Capitalization$418.32 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Entrada Therapeutics alerts: Email Address Entrada Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.1% Upside$21.00 Price TargetShort InterestBearish9.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 7 Articles This WeekInsider TradingAcquiring Shares$119,272 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.54) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.19 out of 5 starsMedical Sector555th out of 930 stocksPharmaceutical Preparations Industry252nd out of 423 stocks 3.5 Analyst's Opinion Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.90% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 23.2, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 1.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRDA. Previous Next 3.8 News and Social Media Coverage News SentimentEntrada Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Entrada Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for TRDA on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have bought 695.15% more of their company's stock than they have sold. Specifically, they have bought $119,272.00 in company stock and sold $15,000.00 in company stock.Percentage Held by InsidersOnly 7.58% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from ($1.54) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -47.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -47.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Birch GoldIRS Loophole Gives Americans An Escape From InflationIn the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.Request your info kit on gold now About Entrada Therapeutics Stock (NASDAQ:TRDA)Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More TRDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRDA Stock News HeadlinesApril 11, 2024 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,600 SharesApril 2, 2024 | insidertrades.comPeter S. Kim Acquires 1,512 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockApril 17, 2024 | Birch Gold (Ad)IRS Loophole Gives Americans An Escape From InflationIn the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.March 27, 2024 | insidertrades.comPeter S. Kim Acquires 3,180 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockMarch 22, 2024 | insidertrades.comInsider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Purchases 900 Shares of StockApril 14, 2024 | nasdaq.comFriday 4/12 Insider Buying Report: ATOS, TRDAApril 12, 2024 | americanbankingnews.comInsider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Acquires 2,600 Shares of StockApril 12, 2024 | insidermonkey.comInsiders are Piling into These 5 Healthcare Stocks in 2024April 17, 2024 | Birch Gold (Ad)IRS Loophole Gives Americans An Escape From InflationIn the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.April 11, 2024 | msn.comInsiders Buying America's Car-Mart And 2 Other StocksMarch 27, 2024 | finance.yahoo.comDirector Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)March 19, 2024 | finance.yahoo.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's EstimatesMarch 18, 2024 | markets.businessinsider.comEntrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical PipelineMarch 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)March 13, 2024 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comRecap: Entrada Therapeutics Q4 EarningsMarch 13, 2024 | globenewswire.comEntrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Insider TradesJanuary 29, 2024 | finance.yahoo.com‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 StocksJanuary 8, 2024 | finance.yahoo.comAmicus (FOLD) Issues Preliminary Revenue Results for FY23January 6, 2024 | msn.comOppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform RecommendationJanuary 3, 2024 | finance.yahoo.comBEAM Stock Rallies More Than 25% in 3 Months: What Next?January 3, 2024 | finance.yahoo.comEntrada Therapeutics Promotes Nathan J. Dowden to PresidentDecember 28, 2023 | finance.yahoo.comEntrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 SharesDecember 20, 2023 | finance.yahoo.comAnavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAADecember 20, 2023 | finance.yahoo.comRoche's (RHHBY) sBLA for Xolair Gets FDA Priority Review TagDecember 11, 2023 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Dividends: History, Yield and DatesSee More Headlines Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/17/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees159Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$22.00 Low Stock Price Target$20.00 Potential Upside/Downside+65.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,680,000.00 Net Margins-5.18% Pretax Margin9.34% Return on Equity-2.89% Return on Assets-1.39% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual Sales$129.01 million Price / Sales3.31 Cash FlowN/A Price / Cash FlowN/A Book Value$7.26 per share Price / Book1.75Miscellaneous Outstanding Shares33,600,000Free Float31,054,000Market Cap$427.39 million OptionableNot Optionable Beta-0.50 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Dipal Doshi (Age 48)CEO & Director Comp: $902.08kMr. Nathan J. Dowden (Age 53)President & COO Comp: $654.6kDr. Natarajan Sethuraman Ph.D. (Age 62)Chief Scientific Officer Comp: $654.6kMr. Kory James Wentworth CPA (Age 44)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., General CounselMs. Kerry Robert M.S.Senior Vice President of PeopleMs. Karla MacDonaldChief Corporate Affairs OfficerMr. Kevin Healy Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsBiomea FusionNASDAQ:BMEAHarrow HealthNASDAQ:HROWLexicon PharmaceuticalsNASDAQ:LXRXHeron TherapeuticsNASDAQ:HRTXPepGenNASDAQ:PEPGView All CompetitorsInsiders & InstitutionsPeter S KimBought 2,600 shares on 4/8/2024Total: $35,282.00 ($13.57/share)Peter S KimBought 1,512 shares on 3/28/2024Total: $20,790.00 ($13.75/share)Peter S KimBought 3,180 shares on 3/25/2024Total: $42,484.80 ($13.36/share)Peter S KimBought 704 shares on 3/21/2024Total: $9,320.96 ($13.24/share)Peter S KimBought 900 shares on 3/19/2024Total: $11,394.00 ($12.66/share)View All Insider TransactionsView All Institutional Transactions TRDA Stock Analysis - Frequently Asked Questions Should I buy or sell Entrada Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRDA shares. View TRDA analyst ratings or view top-rated stocks. What is Entrada Therapeutics' stock price target for 2024? 2 analysts have issued 1-year target prices for Entrada Therapeutics' stock. Their TRDA share price targets range from $20.00 to $22.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 71.1% from the stock's current price. View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts. How have TRDA shares performed in 2024? Entrada Therapeutics' stock was trading at $15.09 at the beginning of 2024. Since then, TRDA shares have decreased by 18.7% and is now trading at $12.27. View the best growth stocks for 2024 here. When is Entrada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TRDA earnings forecast. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) released its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.22. The business had revenue of $41.85 million for the quarter, compared to analysts' expectations of $27.82 million. Entrada Therapeutics had a negative net margin of 5.18% and a negative trailing twelve-month return on equity of 2.89%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRDA) was last updated on 4/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldIRS Loophole Gives Americans An Escape From InflationBirch GoldThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.